The CoronaVirus Disease 19 (COVID-19) pandemic is a threat of particular concern for people affected by chronic immune-mediated diseases, such as multiple sclerosis (MS), who are often treated with immunomodulatory and immunosuppressive drugs, which may increase the risk of infections in general. At the beginning of the COVID-19 pandemic, empirical guidelines on how to manage treatments for immune-mediated diseases, including MS, were released. Subsequently, the first clinical pictures and data sets have been published, describing the outcomes of COVID-19 in patients with MS treated with immunomodulatory and immunosuppressive drugs. Here we will review available information on how infections by human coronaviruses affect the immune system in untreated subjects and in patients affected by MS treated with drugs which modulate the immune system.
ZhouFYuTDuR, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet2020; 395: 1054–1062.
GiovannoniGHawkesCLechner-ScottJ, et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord2020; 39: 102073.
4.
CronRQChathamWW.The question of whether to remain on therapy for chronic rheumatic diseases in the setting of the covid-19 pandemic. J Rheumatol2020; 47: 200492.
ChuHChan YuenTTShuaiH, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: An observational study. Lancet Microbe2020; 1: E14–E23.
7.
WangYLiuL.The membrane protein of severe acute respiratory syndrome coronavirus functions as a novel cytosolic pathogen-associated molecular pattern to promote beta interferon induction via a toll-like-receptor-related TRAF3-independent mechanism. Mbio2016; 7: e01872.
8.
JinJHuHLiHS, et al. Noncanonical NF-κB pathway controls the production of type I interferons in antiviral innate immunity. Immunity2014; 40: 342–354.
9.
LiuTZhangLJooD, et al. NF-κB signaling in inflammation. Signal Transduct Target Therap2017; 2: 17023.
10.
TayMZPohCMRéniaL, et al. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol2020; 20(6): 363–374.
11.
PoppeMWittigSJuridaL, et al. The NF-κB-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells. PLoS Pathog2017; 13(3): e1006286.
12.
MenacheryVDEisfeldAJSchäferA, et al. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. Mbio2014; 5: e01174.
13.
ChannappanavarRFehrARVijayR, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host & Microbe2016; 19: 181–193.
14.
Blanco-MeloDNilsson-PayantBELiuWC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell2020; 181: 1036–1045; e9.
15.
BastardPRosenLBZhangQ, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science2020; 370: eabd4585.
16.
WongCKLamCWWuAK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol2004; 136(1): 95–103.
17.
MinCKCheonSHaNY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Scientific Reports2016; 6: 25359.
18.
ChenGWuDGuoW, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. Epub ahead of print 29 March 2020. DOI: 10.1172/jci137244.
19.
TanLWangQZhangD, et al. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal Trans Target Therap2020; 5: 33.
20.
The Lancet H. COVID-19 coagulopathy: An evolving story. The Lancet Haematology2020; 7: e425.
21.
MiesbachW.Pathological role of angiotensin II in severe COVID-19. TH Open2020; 4(2): e138–e144.
22.
EdwardsJADenisFTalbotPJ.Activation of glial cells by human coronavirus OC43 infection. J Neuroimmunol2000; 108: 73–81.
23.
CoxRJBrokstadKA.Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol2020; 20(10): 581–582.
24.
HsuehPRHuangLMChenPJ, et al. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect2004; 10(12): 1062–1066.
25.
LongQXLiuBZDengHJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Med2020; 26: 845–848.
26.
GrifoniAWeiskopfDRamirezSI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell2020; 181: 1489–1501; e1415.
27.
RobbianiDFGaeblerCMueckschF, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature2020; 584: 437–442.
28.
LiuWFontanetAZhangPH, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis2006; 193: 792–795.
29.
IbarrondoFJFulcherJAGoodman-MezaD, et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild covid-19. N Engl J Med2020; 383: e74.
LaroniAUccelliA.CD56bright natural killer cells: A possible biomarker of different treatments in multiple sclerosis. J Clin Med2020; 9: 1450.
34.
LouapreCCollonguesNStankoffB, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol2020; 77: 1–10.
35.
SormaniMP.An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol2020; 19(6): 481–482.
GandogliaIIvaldiFLaroniA, et al. Teriflunomide treatment reduces B cells in patients with MS. Neurol Neuroimmunol Neuroinflamm2017; 4(6): e403.
38.
WilliamsJWJavaidBKadambiPV, et al. Leflunomide for polyomavirus type BK nephropathy. New Engl J Med2005; 352: 1157–1158.
39.
BowenJDBrinkJBrownTR, et al. COVID-19 in MS: Initial observations from the Pacific Northwest. Neurol Neuroimmunol Neuroinflamm2020; 7: 783.
40.
LinkerRALeeDHRyanS, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain2011; 134(Pt3): 678–692.
41.
OlagnierDFarahaniEThyrstedJ, et al. Identification of SARS-CoV2-mediated suppression of NRF2 signaling reveals a potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Research Square, 2020, https://www.biorxiv.org/content/10.1101/2020.07.16.206458v1
42.
FoxRJMillerDHPhillipsJT, et al. Placebo-controlled phase 3 study of Oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367: 1087–1097.
43.
Sainz de la MazaSMedinaSVillarrubiaN, et al. Factors associated with dimethyl fumarate-induced lymphopenia. J Neurol Sci2019; 398: 4–8.
44.
BarrTAShenPBrownS, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exper Med2012; 209: 1001–1010.
45.
Bar-OrAFawazLFanB, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS. Ann Neurol2010; 67(4): 452–461.
46.
LunaGAlpingPBurmanJ, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2019; 77: 3365.
47.
SahraianMAAzimiANavardiS, et al. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord2020; 46: 102472.
48.
SafaviFNourbakhshBAzimiAR.B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord2020; 43: 102195.
49.
Bar-OrACalkwoodJCChognotC, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology2020; 95: e1999–e2008.
50.
LucchiniMBiancoADel GiacomoP, et al. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report. Mult Scler Relat Disord2020; 44: 102323.
51.
ConteWL.Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia. Mult Scler Relat Disord2020; 44: 102315.
52.
CellerinoMIvaldiFPardiniM, et al. Impact of treatment on cellular immunophenotype in MS: A cross-sectional study. Neurol Neuroimmunol Neuroinflamm2020; 7(3): 693.
53.
MohammedSHarikumarKB.Sphingosine 1-phosphate: A novel target for lung disorders. Front Immunol2017; 8: 296.
54.
EpsteinDJDunnJDeresinskiS.Infectious complications of multiple sclerosis therapies: Implications for screening, prophylaxis, and management. Open Forum Infect Dis2018; 5(8): ofy174.
55.
BakerDHerrodSSAlvarez-GonzalezC, et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflam2017; 4: e360.
56.
TimmermansSSouffriauJLibertC.A general introduction to glucocorticoid biology. Front Immunol2019; 10: 01545.
57.
LuSZhouQHuangL, et al. Effectiveness and safety of glucocorticoids to treat COVID-19: A rapid review and meta-analysis. Ann Transl Med2020; 8(10): 627–627.
FarezMFCorrealeJArmstrongMJ, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology2019; 93: 584–594.
61.
KapposLMehlingMArroyoR, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology2015; 84: 872–879.
62.
MetzeCWinkelmannALoebermannM, et al. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies. CNS Neurosci Ther2019; 25(2): 245–254.
63.
GiovannoniG.Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. Mult Scler Relat Disord2020; 41: 102135.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
